Showing results (21-30 of 38) with videos related to

Sort By:
Pageof 4
Multiple Sclerosis and Related Disorders|September 21, 2016
Safety and tolerability profile of daclizumab in patients with relapsing-remitting multiple sclerosis: An integrated analysis of clinical studiesGavin Giovannoni, Ludwig Kappos, Ralf Gold, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|April 30, 2015
Prolonged-release fampridine and walking and balance in MS: randomised controlled MOBILE trialRaymond Hupperts, Jan Lycke, Christine Short, et al.
Small (Weinheim an Der Bergstrasse, Germany)|April 1, 2025
Binder-Free MoO<sub>2</sub>-MoO<sub>3</sub> Nanoarrays as High-Performance Anodes for Li-Ion BatteriesGagan Kumar Sharma, Jacob Elkins, Anand B Puthirath, et al.
Lancet (London, England)|April 9, 2013
Daclizumab high-yield process in relapsing-remitting multiple sclerosis (SELECT): a randomised, double-blind, placebo-controlled trialRalf Gold, Gavin Giovannoni, Krzysztof Selmaj, et al.
The Lancet. Neurology|February 19, 2010
Daclizumab in active relapsing multiple sclerosis (CHOICE study): a phase 2, randomised, double-blind, placebo-controlled, add-on trial with interferon betaDaniel Wynn, Michael Kaufman, Xavier Montalban, et al.
Neurology|June 28, 2020
Natalizumab in acute ischemic stroke (ACTION II): A randomized, placebo-controlled trialMitchell S V Elkind, Roland Veltkamp, Joan Montaner, et al.
Advances in Therapy|June 3, 2016
Cutaneous Adverse Events in the Randomized, Double-Blind, Active-Comparator DECIDE Study of Daclizumab High-Yield Process Versus Intramuscular Interferon Beta-1a in Relapsing-Remitting Multiple SclerosisJames G Krueger, Leon Kircik, Firas Hougeir, et al.
The Lancet. Neurology|March 25, 2014
Daclizumab high-yield process in relapsing-remitting multiple sclerosis (SELECTION): a multicentre, randomised, double-blind extension trialGavin Giovannoni, Ralf Gold, Krzysztof Selmaj, et al.
The New England Journal of Medicine|October 8, 2015
Daclizumab HYP versus Interferon Beta-1a in Relapsing Multiple SclerosisLudwig Kappos, Heinz Wiendl, Krzysztof Selmaj, et al.
BMC Neurology|July 28, 2016
Safety and efficacy of daclizumab in relapsing-remitting multiple sclerosis: 3-year results from the SELECTED open-label extension studyRalf Gold, Ernst-Wilhelm Radue, Gavin Giovannoni, et al.
Pageof 4